Facebook
Twitter
Telegram
Report an ErrorHTG Molecular Diagnostics Balance Sheet 2011-2024 | HTGM
Annual Balance Sheet HTG Molecular Diagnostics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-11.2 M | -4.01 M | -10.8 M | 2.24 M | 23.9 M | -1.21 M | 4.27 M | 7.56 M | 7.64 M | -1.77 M | -7.11 M | - |
Long Term Debt |
546 K | 5.18 M | 8.57 M | 6.87 M | 9.68 M | 2.96 M | 5.39 M | 7.79 M | 10.4 M | 44.1 K | 205 K | - |
Long Term Debt Current |
475 K | 414 K | 685 K | 759 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
4.1 M | - | 13.5 M | 12.3 M | 15.7 M | 11 M | 14 M | 16.2 M | 29.5 M | 24.5 M | 24.9 M | - |
Total Current Liabilities |
8.27 M | 9.94 M | 7.24 M | 8.9 M | 7.02 M | 13.3 M | 10 M | 6.32 M | - | - | - | - |
Total Liabilities |
12.4 M | 20.1 M | 20.7 M | 21.1 M | 22.7 M | 24.3 M | 24 M | 22.6 M | 32.8 M | 26.8 M | 26.7 M | - |
Deferred Revenue |
- | - | 185 K | 426 K | 333 K | 666 K | 336 K | 47.5 K | 41.2 K | 137 K | 95.5 K | - |
Retained Earnings |
-230 M | -208 M | -191 M | -170 M | -151 M | -135 M | -116 M | -89.6 M | -68.2 M | -54.2 M | -42.4 M | - |
Total Assets |
17.8 M | 30.5 M | 35.2 M | 45.1 M | 43.8 M | 21.3 M | 18.5 M | 39.4 M | 8.73 M | 4.4 M | 8.43 M | - |
Cash and Cash Equivalents |
12.2 M | 9.6 M | 22.4 M | 7.62 M | 8.43 M | 9.97 M | 7.51 M | 3.29 M | 3.61 M | - | - | - |
Book Value |
5.39 M | 10.4 M | 14.5 M | 24 M | 21.1 M | -3.06 M | -5.59 M | 16.9 M | -24 M | -22.4 M | -18.3 M | - |
Total Shareholders Equity |
5.39 M | 10.4 M | 14.5 M | 24 M | 21.1 M | -3.06 M | -5.59 M | 16.9 M | -69.7 M | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet HTG Molecular Diagnostics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | 1.3 M | 2.02 M | 4.05 M | 5.18 M | 6.31 M | 7.44 M | 7.05 M | 8.57 M | 8.57 M | 8.57 M | 8.57 M | 6.87 M | 6.87 M | 6.87 M | 39.1 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | 5.6 M | 6.5 M | 8.7 M | 10.1 M | 11.5 M | 11.7 M | 11.5 M | 13.5 M | 14.5 M | - | - | - | - | 15.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | 12.4 M | 16.6 M | 17.2 M | 20.1 M | 19.6 M | 18.9 M | 19.8 M | 20.7 M | 20.7 M | 20.7 M | 20.7 M | 21.1 M | 21.1 M | 21.1 M | 21.1 M | 22.7 M | 22.7 M | 22.7 M | 22.7 M | 24.3 M | 24.3 M | 24.3 M | 24.3 M | 24 M | 24 M | 24 M | 24 M | 22.5 M | 22.5 M | 22.5 M | 22.5 M | 22.5 M | 22.5 M | 22.5 M | 22.5 M | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | 125 K | 213 K | 209 K | 494 K | 185 K | 185 K | 185 K | 185 K | 426 K | 426 K | 426 K | 426 K | 333 K | 333 K | 333 K | 333 K | 666 K | 781 K | 638 K | 255 K | 336 K | 336 K | 336 K | 336 K | 47.5 K | 47.5 K | 47.5 K | 47.5 K | 41.2 K | 41.2 K | 41.2 K | 41.2 K | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | -225 M | -221 M | -215 M | -208 M | -203 M | -199 M | -196 M | -191 M | -191 M | -191 M | -191 M | -170 M | -170 M | -170 M | -170 M | -151 M | -151 M | -151 M | -151 M | -135 M | -135 M | -135 M | -135 M | -116 M | -116 M | -116 M | -116 M | -89.6 M | -89.6 M | -89.6 M | -89.6 M | -68.2 M | -68.2 M | -68.2 M | -68.2 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
- | 13.6 M | 22.2 M | 28.5 M | 30.5 M | 34.5 M | 37.3 M | 36.6 M | 35.2 M | 35.2 M | 35.2 M | 35.2 M | 45.1 M | 45.1 M | 45.1 M | 45.1 M | 43.8 M | 43.8 M | 43.8 M | 43.8 M | 21.3 M | 21.3 M | 21.3 M | 21.3 M | 18.5 M | 18.5 M | 18.5 M | 18.5 M | 39.4 M | 39.4 M | 39.4 M | 39.4 M | 8.73 M | 8.73 M | 8.73 M | 8.73 M | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
- | 3.21 M | 5.76 M | 14.6 M | 9.6 M | 10.2 M | 13.6 M | 21.8 M | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 7.62 M | 7.62 M | 7.62 M | 7.62 M | 8.43 M | 8.43 M | 8.43 M | 8.43 M | 9.97 M | 9.97 M | 9.97 M | 9.97 M | 7.51 M | 7.51 M | 7.51 M | 7.51 M | 3.29 M | 3.29 M | 3.29 M | 3.29 M | 3.61 M | 3.61 M | 3.61 M | 3.61 M | 1.82 M | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
- | 1.21 M | 5.57 M | 11.3 M | 10.4 M | 14.9 M | 18.4 M | 16.8 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 24 M | 24 M | 24 M | 24 M | 21.1 M | 21.1 M | 21.1 M | 21.1 M | -3.06 M | -3.06 M | -3.06 M | -3.06 M | -5.59 M | -5.59 M | -5.59 M | -5.59 M | 16.9 M | 16.9 M | 16.9 M | 16.9 M | -13.7 M | -13.7 M | -13.7 M | -13.7 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
- | 1.21 M | 5.57 M | 11.3 M | 10.4 M | 14.9 M | 18.4 M | 16.8 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 24 M | 24 M | 24 M | 24 M | 21.1 M | 21.1 M | 21.1 M | 21.1 M | -3.06 M | -3.06 M | -3.06 M | -3.06 M | -5.59 M | -5.59 M | -5.59 M | -5.59 M | 16.9 M | 16.9 M | 16.9 M | 16.9 M | -69.7 M | -69.7 M | -69.7 M | -69.7 M | -58.3 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency